Single dose of SA 14-14-2 vaccine provides long-term protection against Japanese encephalitis: a case-control study in Nepalese children 5 years after immunization. drjbtandan@yahoo.com.
In July 1999, a single dose of live-attenuated SA 14-14-2 Japanese encephalitis (JE) vaccine was administered to children living in the Bardiya, Banke and Kailali districts of Nepal. In 2004, the original vaccinated population experienced a fifth seasonal exposure to JE. We performed a case-control study comparing the prevalence of the administration of vaccine in patients with JE hospitalized in the Bardiya and Bheri Zonal hospitals and in age-sex matched controls resident in the Bardiya district. Among the 219 village controls, 114 had been vaccinated (52.1%) while only one of 20 JE cases had received live-attenuated JE vaccine. Five years after administration of a single dose, SA 14-14-2 provided a protective efficacy of 96.2% (CI 73.1-99.9%).
Tandan
J B
JB
Council for Technical Education and Vocational Training, P.O. Box 3546, Sanothimi, Bhaktapur, Kathmandu, Nepal.
Ohrr
Heechoul
H
Sohn
Young Mo
YM
Yoksan
Sutee
S
Ji
Min
M
Nam
Chung Mo
CM
Halstead
Scott B
SB
D000293:Adolescent; D000328:Adult; D016022:Case-Control Studies; D002675:Child, Preschool; D004672:Encephalitis, Japanese / Q000453:epidemiology / Q000276:immunology* / Q000517:prevention & control*; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000032:analysis / Q000276:immunology; D007075:Immunoglobulin M / Q000032:analysis / Q000276:immunology; D022321:Japanese Encephalitis Vaccines / Q000627:therapeutic use*; D008297:Male; D009390:Nepal / Q000453:epidemiology; D014613:Vaccines, Attenuated / Q000627:therapeutic use; D010948:Viral Plaque Assay
D007074:Immunoglobulin G; D007075:Immunoglobulin M; D022321:Japanese Encephalitis Vaccines; D014613:Vaccines, Attenuated